Moreover, Smyd3 has the capacity to modify non‐histone proteins VEGFR (Kunizaki et al., 2007) and MAP3K2 to promote metastasis and Ras/Raf/MEK/ERK signaling (Mazur et al., 2014) in cancer development. The gene discussed is MAP3K2; the disease is cancer.